Asia Economist and CEO, Centennial Asia Advisors

Manu Bhaskaran

Asia Economist and CEO

Centennial Asia Advisors

At Centennial Asia Advisors, we tell it like it is. We have no vested interests, no need for a China wall, and no reason to skew our outlook any other way. With over 30 years experience covering Asia’s political economy, you can be sure our conclusions and analyses are based on the unadulterated facts. Through years of fine-tuning our research methodologies, we deliver a quality of macroeconomic analysis few other houses can match.

Centennial Asia Advisors is an independent research and advisory firm that works with governments, multilateral institutions, financial firms and leading MNCs.

Economic Policy and Strategic Advisors

Macroeconomics

The death of <a href="http://www.rememberingleekuanyew.sg/" target="_blank">Lee Kuan Yew</a>&nbsp;takes away from Singapore the presence of the most important personality in its modern history and is a moment of deep sadness for all Singaporeans including those of us at <a href="http://www.centennialasia.com/" target="_blank">Centennial Asia</a>.His extraordinary leadership at crucial moments in Singapore&rsquo;s history - the traumatic merger and then separation with Malaysia, the confrontation with Indonesia, ethnic tensions, and countless economic challenges and crises - made what is Singapore today. His record of decisiveness and pragmatism and his success in creating strong institutions and a durable national consensus that unites the country mark him out from other leaders of developing nations.<blockquote>Some analysts have suggested that his passing could weaken Singapore, perhaps even create some political instability. The evidence suggests otherwise.</blockquote>

The death of Lee Kuan Yew&nbsp;takes away from Singapore the presence of the most important personality in its modern history and is a moment of deep sadness for all Singaporeans including those of us at Centennial Asia.His extraordinary leadership at crucial moments in Singapore&rsquo;s history - the traumatic merger and then separation with Malaysia, the confrontation with Indonesia, ethnic tensions, and countless economic challenges and crises - made what is Singapore today. His record of decisiveness and pragmatism and his success in creating strong institutions and a durable national consensus that unites the country mark him out from other leaders of developing nations.Some analysts have suggested that his passing could weaken Singapore, perhaps even create some political instability. The evidence suggests otherwise.

Singapore: Lee Kuan Yew's enduring legacy of strong institutions will see Singapore through

Founder of Innovation Research & Advisory firm, Lightbulb Capital

Daniel Liebau

Founder of Innovation Research & Advisory firm

Lightbulb Capital

Thematic (Sector/Industry)

Companies across different industries are building Innovation centers&nbsp; in Singapore, Hong Kong and other cities across Asia and the rest of the world.&nbsp; Some examples include <a target="_blank" href="http://aia-accelerator.com/">AIA</a>, <a target="_blank" href="http://www.3m.com.hk/intl/hk/english/in_hongkong/innovation_center.html">3M</a>, <a target="_blank" href="http://www.mis-asia.com/tech/industries/metlife-announces-futurelab-in-singapore/">MetLife</a> and <a target="_blank" href="https://www.edb.gov.sg/content/edb/en/news-and-events/news/2014-news/p-and-g-opens-250-million-innovation-centre.html">P&amp;G</a> amongst others.&nbsp;While this is a good step in the right direction there are 4 specific points that are worth considering to gauge if the initiative has a chance to create some optionality for future long term growth. Therefore, from an investment perspective it makes sense to evaluate Innovation initiatives in target companies with those points in mind.

Companies across different industries are building Innovation centers&nbsp; in Singapore, Hong Kong and other cities across Asia and the rest of the world.&nbsp;  Some examples include AIA, 3M, MetLife and P&amp;G amongst others.&nbsp;While this is a good step in the right direction there are 4 specific points that are worth considering to gauge if the initiative has a chance to create some optionality for future long term growth. Therefore, from an investment perspective it makes sense to evaluate Innovation initiatives in target companies with those points in mind. 

Can Innovation labs be assessed to pick stocks for your portfolio?

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>On the 23 Dec 2024, tertiary health care provider <a href="https://www.smartkarma.com/entities/talkmed-group-ltd" target="_blank" data-smartkarma-citation="entities:16079:1" rel="noopener">TalkMed (TKMED SP)</a>  <a href="https://links.sgx.com/FileOpen/Press%20Release.ashx?App=Announcement&amp;FileID=828585" target="_blank" rel="noopener">announced</a> an Offer, by way of a Scheme, from Tamarind Health at S$0.456/share, a 20% premium to undisturbed.  </li>
<li>Tamarind is a Singaporean-based, pan-Asian oncology-focused group. As part of the deal, Temasek-backed 65 Equity Partners will subscribe for new shares in Tamarind.</li>
<li>
The Composite Document is now <a href="https://links.sgx.com/FileOpen/TalkMed%20-%20Composite%20Document.ashx?App=Announcement&amp;FileID=850261" target="_blank" rel="noopener">out</a>, with a Court Meeting on the 15th July, and expected payment around the 29th August. The IFA (KPMG) says "fair &amp; reasonable". </li>
</ul>


On the 23 Dec 2024, tertiary health care provider TalkMed (TKMED SP)  announced an Offer, by way of a Scheme, from Tamarind Health at S$0.456/share, a 20% premium to undisturbed.  
Tamarind is a Singaporean-based, pan-Asian oncology-focused group. As part of the deal, Temasek-backed 65 Equity Partners will subscribe for new shares in Tamarind.

The Composite Document is now out, with a Court Meeting on the 15th July, and expected payment around the 29th August. The IFA (KPMG) says "fair &amp; reasonable". 


IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/healthway-medical-corp-ltd" target="_blank" data-smartkarma-citation="entities:561:1" rel="noopener">Healthway Medical Corp (HMED SP)</a> received a delisting proposal from <a href="https://www.smartkarma.com/entities/oue-lippo-healthcare-ltd" target="_blank" data-smartkarma-citation="entities:562:1" rel="noopener">OUE Lippo Healthcare (IHC SP)</a> at S$0.048 per share, a 45.5% premium to the undisturbed price (28 June).</li>
<li>The key conditions are HMED shareholder approval and the offeror and concert parties representing &gt;50% of voting rights (satisfied due to irrevocables).</li>
<li>The offer price is attractive. The EGM is likely to be held in late September. The current price of S$0.046 implies a gross spread of 4.3%.</li>
</ul>



Healthway Medical Corp (HMED SP) received a delisting proposal from OUE Lippo Healthcare (IHC SP) at S$0.048 per share, a 45.5% premium to the undisturbed price (28 June).
The key conditions are HMED shareholder approval and the offeror and concert parties representing &gt;50% of voting rights (satisfied due to irrevocables).
The offer price is attractive. The EGM is likely to be held in late September. The current price of S$0.046 implies a gross spread of 4.3%.


Healthway Medical (HMED SP): OUE Healthcare’s Delisting Offer

<ul>
<li>In principle, <a href="https://www.smartkarma.com/entities/jafco-co-ltd" target="_blank" data-smartkarma-citation="entities:8848:1" rel="noopener">Jafco Co Ltd (8595 JP)</a> still wants to be greenmailed to get Murakami-san out. </li>
<li>
<a href="https://www.smartkarma.com/entities/jardine-cycle-carriage-ltd" target="_blank" data-smartkarma-citation="entities:347:1" rel="noopener">Jardine Cycle &amp; Carriage (JCNC SP)</a>i is expensive here - relative to historical values -  and from an implied stub perspective. And the MSCI inclusion event has now passed.</li>
<li>If you think this is a "risk", then you want to be long when the discount is wide and <a href="https://www.smartkarma.com/entities/softbank-group-corp" target="_blank" data-smartkarma-citation="entities:315:1" rel="noopener">Softbank Group (9984 JP)</a> is monetising assets in some way. </li>
</ul>


In principle, Jafco Co Ltd (8595 JP) still wants to be greenmailed to get Murakami-san out. 

Jardine Cycle &amp; Carriage (JCNC SP)i is expensive here - relative to historical values -  and from an implied stub perspective. And the MSCI inclusion event has now passed.
If you think this is a "risk", then you want to be long when the discount is wide and Softbank Group (9984 JP) is monetising assets in some way. 


Last Week in Event SPACE: JAFCO, Jardine Cycle, Softbank, Star Health

Singapore

Singapore Medical Group operates medical clinics and provides a wide range of general and specialist medical services, including obstetrics and gynecology, oncology, pediatrics, diagnostic imaging, dental, and aesthetic medicine. The company also offers health screening and telemedicine services. It was incorporated in 2005 and is headquartered in Singapore.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Singapore Medical Group (SMG SP)

Singapore: Lee Kuan Yew's enduring legacy of strong institutions will see Singapore through

The death of Lee Kuan Yew takes away from Singapore the presence of the most important personality in its modern history and is a moment of deep...

Manu Bhaskaran

Can Innovation labs be assessed to pick stocks for your portfolio?

Companies across different industries are building Innovation centers in Singapore, Hong Kong and other cities across Asia and the rest of the...

Daniel Liebau

TalkMed (TKMED SP)'s Super Clean Scheme

Super clean deal - 82.99% of the register are supportive. Trading tight at 1.3%/8.4% gross/annualised. If illiquid arbs are your bag, and not in,...

David Blennerhassett

Healthway Medical (HMED SP): OUE Healthcare’s Delisting Offer

The offer price is attractive. The EGM is likely to be held in late September. The current price of S$0.046 implies a gross spread of 4.3%.

Arun George

Last Week in Event SPACE: JAFCO, Jardine Cycle, Softbank, Star Health

The weekend is here! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed...

David Blennerhassett

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)